Our results underlined the significant correlation between subclonal ANK1 mutation, ANK1-driven genes and immune cell infiltration in CRC, suggesting subclonal ANK1 mutation as a prognostic marker plays potential role in immunotherapy for CRC. The gene discussed is ANK1; the disease is colorectal carcinoma.